ARDX - Ardelyx, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.5000
+0.0600 (+2.46%)
As of 10:17AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close2.4400
Open2.5000
Bid2.45 x 1200
Ask2.49 x 1000
Day's Range2.4120 - 2.5136
52 Week Range2.2600 - 8.1000
Volume41,449
Avg. Volume293,360
Market Cap155.336M
Beta (3Y Monthly)3.27
PE Ratio (TTM)N/A
EPS (TTM)-1.01
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.40
Trade prices are not sourced from all markets
  • What Type Of Shareholder Owns Ardelyx Inc’s (NASDAQ:ARDX)?
    Simply Wall St.15 days ago

    What Type Of Shareholder Owns Ardelyx Inc’s (NASDAQ:ARDX)?

    The big shareholder groups in Ardelyx Inc (NASDAQ:ARDX) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership Read More...

  • PR Newswire28 days ago

    Ardelyx Announces FDA Acceptance of the Filing of its New Drug Application for Tenapanor for the Treatment of Patients with IBS-C

    FREMONT, Calif., Nov. 13, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX), today announced that  the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tenapanor for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). Tenapanor, Ardelyx's lead product candidate, is a minimally-systemic small molecule that acts locally in the gastrointestinal (GI) tract to inhibit the sodium transporter NHE3 and reduce sodium uptake from the gut. Ardelyx's NDA submission is supported by a clinical package encompassing more than 3,100 patients and healthy volunteers who have participated in Ardelyx trials and an extensive clinical and preclinical data package supporting the excellent safety profile.

  • Associated Presslast month

    Ardelyx: 3Q Earnings Snapshot

    The Fremont, California-based company said it had a loss of 39 cents per share. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...

  • PR Newswirelast month

    Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights

    Tenapanor Second Registration Trial for Hyperphosphatemia Ongoing; On-Track for Data in 2019 FREMONT, Calif. , Nov. 7, 2018 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), today reported business highlights ...

  • PR Newswire2 months ago

    Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus

    FREMONT, Calif., Oct. 26, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX), today announced the presentation of preclinical data suggesting therapeutic synergy of tenapanor in combination with sevelamer, the current standard-of-care phosphate binder treatment for hyperphosphatemia, or elevated serum phosphorus. The data, showing that the combination meaningfully reduced serum phosphorus, were presented today in a poster titled "Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in rats," at the American Society of Nephrology (ASN) Annual Meeting.

  • GlobeNewswire2 months ago

    Analysis: Positioning to Benefit within Ardelyx, AXT, TG Therapeutics, MarineMax, Oclaro, and BioCryst Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Oct. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • PR Newswire2 months ago

    Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting

    FREMONT, Calif., Oct. 8, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX), today announced that new data from its long-term safety trial of tenapanor for irritable bowel syndrome with constipation (IBS-C), the T3MPO-3 trial, were presented this weekend at the American College of Gastroenterology (ACG) 2018 Annual Meeting. The poster (P0338), titled "An Open Label Long-Term Safety Trial (T3MPO-3) of Tenapanor in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)," was recognized as a Presidential Poster at this year's meeting, a recognition that fewer than five percent of accepted abstracts receive for high quality, novel, unique and interesting research. Tenapanor, Ardelyx's lead product candidate, is a minimally-systemic small molecule that acts locally in the gastrointestinal (GI) tract to inhibit the sodium transporter NHE3 and reduce sodium uptake from the gut.

  • PR Newswire2 months ago

    Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders

    FREMONT, Calif., Oct. 4, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX), today announced that it will hold an investor event called "Renal Day" on Thursday, Oct. 11, 2018, from 8 to 10 a.m. ET in New York City.

  • How Does Investing In Ardelyx Inc (NASDAQ:ARDX) Impact Your Portfolio?
    Simply Wall St.3 months ago

    How Does Investing In Ardelyx Inc (NASDAQ:ARDX) Impact Your Portfolio?

    Anyone researching Ardelyx Inc (NASDAQ:ARDX) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there areRead More...

  • PR Newswire3 months ago

    Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration

    FREMONT, Calif., Sept. 13, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX), today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting U.S. marketing authorization of tenapanor for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). Tenapanor, Ardelyx's lead product candidate, is a minimally-systemic small molecule that acts locally in the gastrointestinal (GI) tract to inhibit the sodium transporter NHE3 and reduce sodium uptake from the gut. "This NDA submission represents an important advancement in the treatment of people with IBS-C," said William Chey, M.D., professor gastroenterology and nutrition at the University of Michigan and an investigator in Ardelyx's IBS-C clinical trials.

  • PR Newswire3 months ago

    Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption

    FREMONT, Calif., Aug. 29, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX), today announced that the novel mechanism of action for tenapanor for the treatment of hyperphosphatemia, or elevated serum phosphorus, has been published in the peer-reviewed journal Science Translational Medicine. Tenapanor, Ardelyx's lead product candidate, is a sodium/hydrogen exchanger 3 (NHE3) inhibitor currently being evaluated in a second, Phase 3 registration trial, the PHREEDOM trial, for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) who are on dialysis. "The elucidation of tenapanor's mechanism is a landmark discovery in our field causing us to completely rethink our understanding of phosphate transport and absorption," said Geoff Block, M.D., director of clinical research at Denver Nephrology Research, and a PHREEDOM trial investigator.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of ARDX earnings conference call or presentation 7-Aug-18 8:30pm GMT

    Q2 2018 Ardelyx Inc Earnings Call

  • Associated Press4 months ago

    Ardelyx: 2Q Earnings Snapshot

    On a per-share basis, the Fremont, California-based company said it had a loss of 42 cents. The biotechnology company posted revenue of $30,000 in the period. In the final minutes of trading on Tuesday, ...

  • PR Newswire4 months ago

    Ardelyx Reports Second Quarter 2018 Financial Results and Recent Highlights

    Operating Runway Extended to Mid-2020 Preparing to Submit NDA for Tenapanor in IBS-C in Early Q4 2018 Conference Call to be Held Today at 4:30 p.m. ET FREMONT, Calif. , Aug. 7, 2018 /PRNewswire/ -- Ardelyx, ...

  • ACCESSWIRE4 months ago

    Ardelyx, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Ardelyx, Inc. (NASDAQ: ARDX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern Time. To listen ...

  • PR Newswire4 months ago

    Ardelyx Announces Date of Second Quarter 2018 Financial Results and Conference Call

    FREMONT, Calif., Aug. 1, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today announced that it plans to report its second quarter 2018 financial results after market close on Tuesday, August 7, 2018. Management will host a conference call and webcast that afternoon at 4:30 p.m. ET to discuss the results and other business updates. To participate in the conference call, please dial (855) 296-9612 (toll-free) or (920) 663-6277 (toll) and reference call ID number 1592643.

  • ACCESSWIRE6 months ago

    Free Technical Reports on Array BioPharma and Three Additional Biotech Equities

    Under observation are these four equities: Ardelyx Inc. (NASDAQ: ARDX), Array BioPharma Inc. (NASDAQ: ARRY), Audentes Therapeutics Inc. (NASDAQ: BOLD), and Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH). All you have to do is sign up today for this free limited time offer by clicking the link below.

  • PR Newswire6 months ago

    Ardelyx to Present at the Jefferies 2018 Global Healthcare Conference

    FREMONT, Calif., May 29, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present a company overview at the Jefferies Global Healthcare Conference on Tuesday, June 5, 2018 at 2:30 p.m. ET in New York City. To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. Ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. Ardelyx's renal pipeline includes the Phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and RDX013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease.

  • Why Ardelyx Inc. Is Down by Double Digits for a Second Day in a Row
    Motley Fool7 months ago

    Why Ardelyx Inc. Is Down by Double Digits for a Second Day in a Row

    The buyers for its secondary stock offering weren't willing to pay up for the biotech.

  • Benzinga7 months ago

    Benzinga's Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech Stocks Hitting 52-week highs on May 22) ArQule, Inc. (NASDAQ: ARQL ) AstraZeneca plc (ADR) (NYSE: ...

  • PR Newswire7 months ago

    Ardelyx Announces Pricing of Public Offering of Common Stock

    FREMONT, Calif., May 22, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $4.00 per share, before underwriting discounts and commissions, for gross proceeds of $50,000,000. In addition, the Company has granted the underwriters of the offering the right for a period of 30 days to purchase up to an additional 1,875,000 shares of common stock at the public offering price, less underwriting discounts and commissions. Ardelyx currently expects to use its existing cash, cash equivalents and short-term investments and the net proceeds of the offering to support its clinical development and pre-commercialization efforts for tenapanor for the treatment of hyperphosphatemia in patients with end-stage renal disease who are on dialysis, including the ongoing second Phase 3 clinical trial evaluating tenapanor for such indication, its manufacturing efforts for tenapanor, research and development efforts for its RDX013 program, the preparation and submission of a New Drug Application for tenapanor for irritable bowel syndrome with constipation and for general corporate purposes and working capital.

  • Benzinga7 months ago

    Benzinga's Daily Biotech Pulse: Melinta, Ardelyx Pull Back On Offerings, Insys Awaits FDA Verdict

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech Stocks Hitting 52-week highs on May 21) AstraZeneca plc (ADR) (NYSE: AZN ) (FDA approved its ...

  • PR Newswire7 months ago

    Ardelyx Raises $50 Million in Loan Agreement with Solar Capital and Bridge Bank

    FREMONT, Calif., May 21, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX), today announced it has entered into a $50.0 million senior secured term loan facility with Solar Capital Ltd. and the Life Sciences Group at Bridge Bank, a division of Western Alliance Bank. "With this additional capital, we have strengthened our position to execute our business strategy of developing disruptive treatments for renal diseases," said Mike Raab, president and chief executive officer of Ardelyx. The loan agreement with Solar Capital Ltd. and Bridge Bank provides for a $50.0 million senior secured term loan facility with a maturity date of November 1, 2022, or approximately 54 months after its initiation, with an interest rate of 7.45 percent plus the 30-day LIBOR.